Behnam Nazari

Title: Behnam Nazari: Innovator in Biosynthetic Gene Activation

Introduction

Behnam Nazari is a prominent inventor based in Princeton, NJ (US). He has made significant contributions to the field of biosynthetic gene activation, particularly in Actinomycete bacteria. His innovative work has led to the discovery of novel metabolites with potential therapeutic applications.

Latest Patents

Behnam Nazari holds a patent titled "Cryptic metabolites and method for activating silent biosynthetic gene clusters in actinomycete bacteria." This patent discloses a high-throughput transcriptional assay format that utilizes eGFP as a read-out for secondary metabolite synthesis. The approach successfully induced a silent gene cluster in J1074, revealing cytotoxins such as etoposide and ivermectin as potent inducers. This work has allowed for the isolation and structural characterization of nearly 20 novel small molecule products, including a new antifungal and several inhibitors of a cysteine protease implicated in cancer. The research also identified a pathway-specific transcriptional repressor that silences the gene cluster under normal growth conditions. This innovative method paves the way for future discoveries of cryptic metabolites with useful bioactivities from Actinomycete bacteria.

Career Highlights

Behnam Nazari is affiliated with Princeton University, where he conducts his research. His work has garnered attention for its potential impact on drug discovery and the understanding of biosynthetic pathways in bacteria.

Collaborations

He has collaborated with notable colleagues, including Mohammad R Seyedsayamdost and Fei Xu, to advance his research in the field.

Conclusion

Behnam Nazari's contributions to the activation of silent biosynthetic gene clusters represent a significant advancement in the field of microbiology and drug discovery. His innovative approaches are likely to lead to the identification of new therapeutic agents in the future.